Pfizer Inc. (NYSE:PFE) Position Increased by Montecito Bank & Trust

Montecito Bank & Trust boosted its position in Pfizer Inc. (NYSE:PFE) by 14.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 41,592 shares of the biopharmaceutical company’s stock after purchasing an additional 5,217 shares during the quarter. Montecito Bank & Trust’s holdings in Pfizer were worth $1,204,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Woodmont Investment Counsel LLC grew its holdings in Pfizer by 40.4% in the 3rd quarter. Woodmont Investment Counsel LLC now owns 227,489 shares of the biopharmaceutical company’s stock worth $6,584,000 after buying an additional 65,424 shares in the last quarter. WoodTrust Financial Corp increased its stake in Pfizer by 12.9% during the 3rd quarter. WoodTrust Financial Corp now owns 325,370 shares of the biopharmaceutical company’s stock valued at $9,416,000 after buying an additional 37,078 shares during the period. Vickerman Investment Advisors Inc. raised its holdings in Pfizer by 0.7% during the third quarter. Vickerman Investment Advisors Inc. now owns 61,636 shares of the biopharmaceutical company’s stock worth $1,784,000 after purchasing an additional 438 shares in the last quarter. Walkner Condon Financial Advisors LLC bought a new position in Pfizer during the 3rd quarter valued at $257,000. Finally, Advisor Resource Council acquired a new position in shares of Pfizer during the 3rd quarter valued at $229,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Price Performance

NYSE PFE opened at $27.35 on Thursday. The stock has a market capitalization of $154.98 billion, a PE ratio of 36.96, a price-to-earnings-growth ratio of 0.88 and a beta of 0.67. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a 50 day moving average price of $28.96 and a two-hundred day moving average price of $28.64. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The company’s revenue was up 31.2% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.14%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PFE. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company increased their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.